Opexa Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1986-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
- Conditions
- Autoimmune Diseases of the Nervous SystemMultiple SclerosisSecondary Progressive Multiple SclerosisDisease ProgressionBrain Atrophy
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT01684761
- Locations
- 🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸Northwest NeuroSpecialists, LLC, Tucson, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, The Research and Education Development Institute, Berkeley, California, United States
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
- Conditions
- Clinically Isolated SyndromeMultiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00595920
- Locations
- 🇺🇸
North Central Neurology Associates, PC, Cullman, Alabama, United States
🇺🇸Xenoscience - 21st Century Neurology, Phoenix, Arizona, United States
🇺🇸HOPE Research Institute, Phoenix, Arizona, United States
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00587691
- Locations
- 🇺🇸
Bellaire Neurology, Bellaire, Texas, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Opexa Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00245622
- Locations
- 🇺🇸
North Central Neurology Associates, PC, Cullman, Alabama, United States
🇺🇸Xenoscience - 21st Century Neurology, Phoenix, Arizona, United States
🇺🇸HOPE Research Institute, Phoenix, Arizona, United States